Painful diabetic polyneuropathy: Approach to diagnosis and management

Clinical Journal of Pain

Volumn 28, Issue 8, 2012, Pages 726-743

  Spallone, Vincenza ^a   Lacerenza, Marco ^b   Rossi, Andrea ^c   Sicuteri, Riccardo ^c   Marchettini, Paolo ^d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Pain Medicine Center   (Italy)

^c Medical Department   (Italy)

^d Istituto San Raffaele di Milano   (Italy)

Author keywords

diabetic neuropathy; diagnosis; neuropathic; pain; therapy

Indexed keywords

AMINOLEVULINIC ACID; AMITRIPTYLINE; BOTULINUM TOXIN; DESIPRAMINE; DULOXETINE; GABAPENTIN; GLYCERYL TRINITRATE; HARKOSERIDE; IMIPRAMINE; LAMOTRIGINE; LIDOCAINE; OXCARBAZEPINE; OXYCODONE; PREGABALIN; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ALGORITHM; ASTHENIA; ATAXIA; COMORBIDITY; CONSTIPATION; DECREASED APPETITE; DIABETES CONTROL; DIABETIC NEUROPATHY; DIAGNOSTIC APPROACH ROUTE; DISEASE SEVERITY; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HEADACHE; HEART FAILURE; HUMAN; HYPERHIDROSIS; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NAUSEA; NEUROPATHIC PAIN; PAINFUL DIABETIC POLYNEUROPATHY; PATHOGENESIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCREENING TEST; SEDATION; SIDE EFFECT; SOMNOLENCE; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

DIABETIC NEUROPATHIES; HUMANS; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; QUALITY OF LIFE;

EID: 84865640344     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e318243075c     Document Type: Review

References (148)

1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635. (Pubitemid 351620320)
2. Marchettini P, Simone DA, Caputi G, et al. Pain from excitation of identified muscle nociceptors in humans. Brain Res. 1996;740:109-116. (Pubitemid 26411289)
3. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007;10:1361-1368. (Pubitemid 350014681)
4. Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. Pain. 2008;137:473-477.
5. Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify neuropathic pain. Pain. 2007;127:199-203. (Pubitemid 46084881)
6. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248-257. (Pubitemid 38353047)
7. Bennett MI, Smith BH, Torrance N, et al. The S-LANSS Score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6:149-158. (Pubitemid 40365018)
8. Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain. 2003;19:306-314. (Pubitemid 37075671)
9. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29-36. (Pubitemid 40279084)
10. Freyhagen R, Baron R, Gockel U, et al. painDETECT: a new screening questionnaire to detect neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911-1920. (Pubitemid 44663395)
11. Portenoy R. Development and testing of a neuropathic pain screening questionnaire: ID pain. Curr Med Res Opin. 2006;22:1555-1565. (Pubitemid 44297434)
12. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248-257. (Pubitemid 38353047)
13. Dworkin RH, Turk DC, Revicki DA, et al. Development and initial validation of an expanded and revised version of the Short-Form McGill Pain Questionnaire (SF-MPQ-2). Pain. 2009;144:35-42.
14. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17:197-210. (Pubitemid 13012221)
15. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9: 105-121. (Pubitemid 351147828)
16. Cruccu G, Truini A. Tools for assessing neuropathic pain. PLoS Med. 2009;6:e10000045.
17. Lauria G, Hsieh ST, Johansson O, et al. European Federation of Neurological Societies; Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:903-912; e44-e49.
18. Stephenson DT, Arneric SP. Neuroimaging of pain: advances and future prospects. J Pain. 2008;9:567-579.
19. Cruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010;17:1010-1008.
20. Rolke R, Baron R, Maier C, et al. A quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and references values. Pain. 2006;123:231-243.
21. Scholz J, Mannion RJ, Hord DE, et al. A novel tool for the assessment of pain: validation in low back pain. PLoS Med. 2009;6:e1000047.
22. Sadosky A, McDermott AM, Brandenburg NA, et al. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia and less commonly studied neuropathic pain conditions. Pain Pract. 2008;8:45-56.
23. Tesfaye S, Boulton AJ, Dyck PJ, et al. Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285-2293.
24. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev. 2008;24:S52-S57. (Pubitemid 351802772)
25. Boulton AJ, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458-1486. (Pubitemid 38680000)
26. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387-397. (Pubitemid 46148513)
27. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009;35:206-213.
28. Davies M, Brophy S, Williams R, et al. The prevalence, severity and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518-1522. (Pubitemid 44127574)
29. Ziegler D, Rathmann W, Dickhaus T, et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy. The MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008; 31:464-469.
30. Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976-982. (Pubitemid 39215316)
31. Hall GC, Carroll D, Parry D, et al. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006;122:156-162.
32. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341-350.
33. Panero F, Novelli G, Zucco C, et al. Fasting plasma C-peptide and micro-and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care. 2009;32:301-305.
34. Spallone V, Morganti R, D'Amato C, et al. Clinical correlates of painful diabetic neuropathy and relationship of neuropathic pain with sensorimotor and autonomic nerve function. Eur J Pain. 2011;15:153-160.
35. Ellenberg M. Diabetic neuropathic cachexia. Diabetes. 1974;23:418-423.
36. Archer AG, Watkins PJ, Thomas PK, et al. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry. 1983;46:491-499. (Pubitemid 13099694)
37. Said G, Lacroix C, Lozeron P, et al. Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain. 2003;126:376-385. (Pubitemid 36172742)
38. Llewelyn JG, Thomas PK, Fonseca V, et al. Acute painful diabetic neuropathy precipitated by strict glycaemic control. Acta Neuropathol. 1986;72:157-163. (Pubitemid 17010790)
39. Garland HT. Diabetic amyotrophy. Br Med J. 1955;2:1287-1290.
40. Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 1999;53:2113-2121.
41. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1-32.
42. Baron R. Mechanisms of disease: neuropathic pain-a clinical perspective. Nat Clin Pract Neurol. 2006;2:95-106. (Pubitemid 43210250)
43. Cole BE. Diabetic peripheral neuropathic pain: recognition and management. Pain Med. 2007;8:S27-S32.
44. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis and treatment options. Pain Med. 2008;9:660-674.
45. Tanabe M, Shimizu S, Takabayashi K, et al. Functional alteration of inhibitory influences on spinal motor output in painful diabetic neuropathy in rats. Neurosci Lett. 2005;389:152-156. (Pubitemid 41267217)
46. Fischer TZ, Waxman SG. Neuropathic pain in diabetes\evidence for a central mechanism. Nat Rev Neurol. 2010; 6:462-426.
47. Turgut N, Altun BU. Cortical disinhibition in diabetic patients with neuropathic pain. Acta Neurol Scand. 2009;120:383-388.
48. Obrosova IG. Diabetes and the peripheral nerve. Biochim Biophys Acta. 2009;1792:931-940.
49. Zochodne DW. Diabetic polyneuropathy: an update. Curr Opin Neurol. 2008;21:527-533.
50. Smith RG. Painful diabetic peripheral neuropathy. J Am Podiatr Med Assoc. 2007;97:394-401.
51. Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss and small nerve fibers in diabetes. Diabetes Care. 2006;29:883-887. (Pubitemid 44115311)
52. Quattrini C, Tavakoli M, Jeziorska M, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes. 2007;56:2148-2154. (Pubitemid 47195833)
53. O'Connor AB. Neuropathic pain: quality of life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009; 27:95-112.
54. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68:1178-1182. (Pubitemid 46608464)
55. Krein SL, Heisler M, Piette JD, et al. The effect of chronic pain on diabetes patients' self-management. Diabetes Care. 2005;28:65-70. (Pubitemid 40095784)
56. Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain. 2006;22:681-685. (Pubitemid 44434950)
57. De Micheli A. Italian standards for diabetes mellitus 2007: executive summary: Diabete Italia, AMD Associazione Medici Diabetologi, SID Societa Italiana di Diabetologia. Acta Diabetol. 2008;45:107-127.
58. Young RJ. Structural functional interactions in the natural history of diabetic polyneuropathy: a key to the understanding of neuropathic pain? Diabet Med. 1993;10:89S-90S. (Pubitemid 23162715)
59. Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281-1289. (Pubitemid 24324972)
60. Fedele D, Comi G, Coscelli C, et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian Diabetic neuropathy Committee. Diabetes Care. 1997;20:836-843. (Pubitemid 27202538)
61. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64:199-207.
62. Haanpaa ML, Backonja MM, Bennett MI, et al. Assessment of neuropathic pain in primary care. Am J Med. 2009; 122(suppl 10):S13-S21.
63. Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med. 1998;15:508-514. (Pubitemid 28261150)
64. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956-962. (Pubitemid 40434506)
65. Shy ME, Frohman EM, So YT, et al. Quantitative sensory testing: report on the Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003;60:898-904. (Pubitemid 36348918)
66. Perkins BA, Olaleye D, Zinman B, et al. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001;24:250-256. (Pubitemid 32119120)
67. Spallone V. Painful diabetic neuropathy: diagnostic and therapeutical approach to an emerging problem. MeDia. 2009;9:1-14.
68. Lacerenza M. Painful diabetic neuropathis. Case reports and diagnostic criteria. Pathos. 2006;13:10-22.
69. England JD, Gronseth GS, Franklin G, et al. Practice parameter: the evaluation of distal symmetric polyneurop-athy: the role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2009;1:5-13.
70. Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010;33:1090-1096.
71. Dyck PJ, Dyck PJ, Klein CJ, et al. Does impaired glucose metabolism cause polyneuropathy? Review of previous studies and design of a prospective controlled population-based study. Muscle Nerve. 2007;36:536-541. (Pubitemid 47512081)
72. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29: 1294-1299. (Pubitemid 44125925)
73. Ziegler D, Rathmann W, Meisinger C, et al. Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. Eur J Pain. 2009;13:582-587.
74. Ziegler D, Rathmann W, Dickhaus T, et al. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10:393-400.
75. Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21:114-121. (Pubitemid 38221809)
76. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alfa-lipoic acid improves symptomatic diabetic polyneuro-pathy: the SYDNEY 2 trial. Diabetes Care. 2006;29: 2365-2370. (Pubitemid 44912237)
77. Mijnhout GS, Alkhalaf A, Kleerfstra N, et al. Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes? Neth J Med. 2010;68:158-162.
78. Ziegler D, Low PA, Boulton AJM. Antioxidant treatment with alpha-lipoic acid in diabetic polyneuropathy: a 4-year randomized double-blind trial (NATHAN 1). Diabetologia. 2007;50:S63.
79. Boulton AJ. Whither clinical research in diabetic sensorimo-tor peripheral neuropathy? Problems of end point selection for clinical trials. Diabetes Care. 2007;30:2752-2753. (Pubitemid 47547832)
80. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: Consensus Recommendations on Diagnosis, Assessment and management. Diabetes Metab Res Rev. 2011;27:629-638.
81. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy. Neurology. 2011;76:1758-1765.
82. Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain. 2006;7:892-900. (Pubitemid 44854739)
83. Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006;81:S3-S11.
84. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms and treatment. Lancet Neu-rol. 2010;9:807-819.
85. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007; 151:737-748. (Pubitemid 47075311)
86. Wong MC, Chung JWY, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. 2007;335:87.
87. Jose VM, Bhansali A, Hota D, et al. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med. 2007;24:377-383. (Pubitemid 46452398)
88. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007 Oct 17; CD005454.
89. Gidal B. New and emerging treatment options for neuropathic pain. Am J Manag Care. 2006;12:S269-S278. (Pubitemid 43993105)
90. Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110:697-706. (Pubitemid 39036802)
91. Raskin J, Pritchett L, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346-356. (Pubitemid 41727332)
92. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116: 109-118. (Pubitemid 40828506)
93. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411-1420. (Pubitemid 44632065)
94. Pritchett YL, McCarberg BH, Watkin JG, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile. Pain Med. 2007;8:397-409. (Pubitemid 47163277)
95. Hall JA, Wang F, Oakes TM, et al. Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials. Expert Opin Drug Saf. 2010;9: 525-537.
96. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2009 Oct 7; CD007115.
97. Robinson-Papp J, Simpson DM. Safety profile of treatment in diabetic peripheral neuropathic pain. Pain Med. 2007; 8:S43-S49. (Pubitemid 47288510)
98. Ziegler D, Pritchett YL, Wang F, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care. 2007;30: 664-669. (Pubitemid 46354350)
99. Wernicke JF, Prakash A, Kajdasz DK, et al. Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. J Diabetes Complications. 2009;23:349-359.
100. Wasan AD, Ossanna MJ, Raskin J, et al. Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients. Curr Drug Saf. 2009; 4:22-29.
101. Fishbain DA, Hall JA, Risser RC, et al. Does pain cause the perception of fatigue in patients with chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine. Pain Pract. 2009;9:354-362.
102. Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain. Diabetes Metab Res Rev. 2009; 25:623-631.
103. Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM. 2004;97:33-38. (Pubitemid 38195700)
104. Rauck RL, Shaibani A, Biton V, et al. Lacosamide in painful diabetic peripheral neuropathy. a phase 2 double-blind placebo-controlled study. Clin J Pain. 2007;23:150-158. (Pubitemid 46150939)
105. Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain. 2007;128:169-179. (Pubitemid 46216610)
106. Dogra S, Beydoun S, Mazzola J, et al. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain. 2005;9:543-554. (Pubitemid 41219786)
107. Beydoun A, Shaibani A, Hopwood M, et al. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol Scand. 2006;113:395-404. (Pubitemid 44046325)
108. Thienel U, Neto W, Schwabe SK, et al. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand. 2004;110:221-231. (Pubitemid 39274056)
109. Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology. 2004;63:865-873. (Pubitemid 39297649)
110. Shaibani A, Fares S, Selam JL, et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain. 2009;10:818-828.
111. Wymer JP, Simpson J, Sen D, et al. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain. 2009;25:376-385.
112. Ziegler D, Hidvegi T, Gurieva I, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care. 2010;33:839-841.
113. Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin-calcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain. 2009;142:13-16.
114. Sandercock D, Cramer M, Wu J, et al. Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. Diabetes Care. 2009;32:e20.
115. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Co-chrane Database Syst Rev. 2011 Mar 16; CD007938.
116. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104-2110. (Pubitemid 39636259)
117. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-638. (Pubitemid 39036794)
118. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253-260. (Pubitemid 40488803)
119. Tolle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12:203-213. (Pubitemid 350180540)
120. Arezzo JC, Rosenstock J, Lamoreaux L, et al. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.
121. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008; 31:1448-1454.
122. Bansal D, Bhansali A, Hota D, et al. Amitriptyline vs pregabalin in painful diabetic neuropathy: a randomized, double-blind clinical trial. Diabet Med. 2009;26:1019-1026.
123. Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009 Jul 8; CD007076.
124. Quilici S, Chancellor J, Lothgren M, et al. Meta-analysis of duloxetine vs pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9:6.
125. Webster L, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. J Pain. 2010;11:602-611.
126. Reeves RR, Burke RS. Tramadol: basic pharmacology and emerging concepts. Drugs Today. 2008;11:827-836.
127. Argoff CE. The coexistence of neuropathic pain, sleep and psychiatric disorders: a novel treatment approach. Clin J Pain. 2007;23:15-22.
128. Portenoy RK, Farrar JT, Backonja MM, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23:287-299. (Pubitemid 46650020)
129. Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25:1663-1676.
130. Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin. 2009;25:1677-1687.
131. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289-305. (Pubitemid 41752987)
132. Agrawal RP, Choudhary R, Sharma P, et al. Glyceryl trinitrate spray in the management of painful diabetic neuropathy: a randomized double-blind placebo-controlled cross-over study. Diabetes Res Clin Pract. 2007;77:161-167. (Pubitemid 46670414)
133. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72:1473-1478.
134. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neuro-toxicology. 2005;26:785-793. (Pubitemid 41427518)
135. Pieber K, Herceg M, Paternostro-Sluga T. Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review. J Rehabil Med. 2010;42:289-295.
136. Daousi C, Benbow SJ, MacFarlane IA. Electrical spinal cord stimulation in the long-term treatment of chronic painful diabetic neuropathy. Diabet Med. 2005;22:393-398. (Pubitemid 40516236)
137. Bosi E, Conti M, Vermigli C, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia. 2005;48:817-823. (Pubitemid 40767972)
138. Swislocki A, Orth M, Bales M, et al. A randomized clinical trial of the effectiveness of photon stimulation on pain, sensation and quality of life in patients with diabetic peripheral neuropathy. J Pain Symptom Manag. 2010;39:88-99.
139. Dubinsky RM, Miyasaki J. Assessment: efficacy of trans-cutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74: 173-176.
140. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmaco-logic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237-251. (Pubitemid 350051570)
141. National Institute for Health and Clinical Excellence. Neuropathic pain. The pharmacological management of neuropathic pain in adults in non-specialist settings. NICE clinical guideline 96 issue date: March 2010. Available at: http://www.nice.org.uk/nicemedia/live/12948/47949/47949.pdf.
142. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of clinical endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. End Pract. 2011;17:1-51.
143. Vinik A. The approach to the management of the patient with neuropathic pain. Pain J Clin Endocinol Metab. 2010;95: 4802-4811.
144. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin or their combination for neuropathic pain. N Engl J Med. 2005; 352:1324-1334. (Pubitemid 40411499)
145. Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomized controlled crossover trial. Lancet. 2009;374:1252-1261.
146. Hanna M, O'Brien C, Wilson MC. Prolonged-release oxy-codone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain. 2008;12: 804-813.
147. Zin CS, Nissen LM, O'Callaghan JP, et al. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain. 2010;11:462-471.
148. Quattrini C, Tesfaye S. Understanding the impact of painful diabetic neuropathy. Diabetes Metab Res Rev. 2003;19:S2-S8. (Pubitemid 36285366)